辅助生殖技术纳入医保的实践与思考  

The Practice and Reflections on the Inclusion of Assisted Reproductive Technologies in Medical Insurance

作　　者：贾溜溜 胡琳琳[1] 肖丹妮 

机构地区：[1]北京协和医学院卫生健康管理政策学院,北京100193

出　　处：《中国医疗保险》2025年第4期23-29,共7页China Health Insurance

基　　金：中国医学科学院医学与健康科技创新工程“基于卫生健康体系学的健康中国建设战略研究”(2021-I2M-1-046)。

摘　　要：近年来,我国的生育率持续走低,为顺应积极的生育政策、减轻不孕不育人群接受医疗服务的经济负担,全国范围内正在加速推进辅助生殖技术纳入医保。本研究参考典型国家将辅助生殖技术纳入医保的政策实践,分析了我国辅助生殖技术纳入医保政策的实施现状,发现我国政策运行已取得显著进展,但医保政策支持辅助生殖的有效性和可持续性尚存在一定挑战。在政策设计和执行过程中,还需动态优化辅助生殖的医保制度设计、逐步扩展辅助生殖领域的医保支付范围、加强宏观规划和管理,以促进辅助生殖技术公平可及,从而进一步提高辅助生殖技术纳入医保政策的有效性和可持续性。In recent years,China's fertility rate has remained at a low level.In order to comply with the positive fertility policy and reduce the economic burden of infertile individuals receiving medical services,the inclusion of assisted reproductive technology(ART) in medical insurance is accelerating countrywide.This study learns from the policy and practice of typical countries including ART in medical insurance abroad,analyzes the implementation status of including ART in medical insurance,and finds that China has made significant progress in incorporating ART into medical insurance.However,there are challenges to the effectiveness and sustainability of medical insurance policies supporting assisted reproduction.In the process of policy design and implementation,it is necessary to dynamically optimize the medical insurance system design of ART,gradually expand the scope of medical insurance coverage for ART,and strengthen macro-level planning and management to promote equitable access to ART,in order to further improve the effectiveness and sustainability of including ART in medical insurance policies.

关 键 词：辅助生殖技术 生育支持政策 医疗保险 卫生政策 

分 类 号：F840.684[经济管理—保险]